Metabolomics reveals reasons for the efficacy of acupuncture in 1 migraine patients: The role of anaerobic glycolysis and mitochondrial 2 citrate in migraine relief 3 Zishan Gao^{1,2,3,4*}, Xianzhong Yan⁵, Rui Wang-Sattler^{1,2}, Marcela Covic^{1,2}, Guang Yu⁶, 4 Feifei Ge⁷, Jia Lin⁸, Qin Chen⁹, Juan Liu⁵, Sapna Sharma^{1,2}, Sophie Molnos^{1,2}, Brigitte 5 Kuehnel^{1,2}, Rory Wilson^{1,2}, Jonathan Adam^{1,2}, Stefan Brandmaier^{1,2}, Shuguang Yu¹⁰, 6 Ulrich Mansmann⁴, Fanrong Liang^{11*}, Christian Gieger^{1,2*} 7 1 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German 8 9 Research Center for Environmental Health, Neuherberg, Bavaria, Germany 10 2 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for 11 Environmental Health, Neuherberg, Bavaria, Germany 3 Department of Clinical Acupuncture and Moxibustion, Nanjing University of Chinese 12 13 Medicine, Nanjing, Jiangsu 210029, China 4 Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-14 Maximilians University Munich, Munich, Germany 15 5 National Center of Biomedical Analysis, Beijing 100039, China 16 6 Department of Biochemistry and Molecular Biology, School of Medicine & Holistic 17 Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, 18 China 19 7 Department of Human Anatomy and Histoembryology, School of Medicine & Holistic 20 Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, 21 China 22 8 Department of Biochemistry and Molecular Biology, West China School of Basic 23 24 Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, 25

20	³ The Third Altimated Hospital of Zhejfang Chinese Medical Oniversity, Hangzhou,								
27	Zhejiang 310006, China								
28	10 Acupuncture & Chronobiology Key Laboratory of Sichuan Province, Chengdu								
29	University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China								
30	11 Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of								
31	Traditional Chinese Medicine, Chengdu, Sichuan 610075, China								
32									
33	For correspondence: zishang30@sina.cn;christian.gieger@helmholtz-muenchen.de;								
34	acuresearch@126.com								
35									
36	Competing interest: The remaining authors declare competing no financial interests.								
37									
38	Abstract								
39	Acupuncture is used worldwide to treat migraine, but its scientific mechanism remains								

O The Third

~

Affiliated Hagnital of Zhajiang Chinaga Madical University Hangzhou

unclear. Here, we report a 1H NMR metabolomics study involving 40 migraine patients 40 and 10 healthy people randomly receiving acupuncture or sham acupuncture, followed by 41 42 machine learning techniques and functional analysis. We found that acupuncture at acupoints particularly enhanced anaerobic glycolysis and modified mitochondrial 43 function by adjusting the levels of plasma pyruvic acid (P = 0.012), lactic acid (P =44 (0.031) and citrate (P = 0.00079) at a Bonferroni-corrected level of significance compared 45 to the pre-treatment level of these three metabolites in migraine patients. Therefore, 46 acupuncture supplies energy to migraine patients and relieves migraine attacks. In 47 contrast, we observed that sham acupuncture may partially supply energy to migraine 48 patients through lipid metabolism by changing the levels of plasma lipid (P = 0.0012), 49 50 glycerine (P = 0.021), and pyruvic acid (P = 0.047) at a Bonferroni-corrected level of significance. The functional network analysis further indicates this different way of supplying energy contributes to the different effects of acupuncture and sham acupuncture. Our findings reveal novel metabolic evidence for the specific effect of acupuncture in relation to sham acupuncture. This metabolic evidence could enlighten a brand new direction into acupuncture analgesia mechanism, which in turn would pose fresh challenges for future acupuncture research.

57 Keywords: migraine; acupuncture; metabolomic; anaerobic glycolysis; citrate; lactic acid
58

59 **Introduction**

Acupuncture is commonly used for preventing and relieving migraine worldwide 60 (Wells et al., 2011). Understanding the mechanism underlying the efficacy of acupuncture 61 for migraine is key to the acceptance of acupuncture as valid therapy for both Western 62 doctors and policymakers. Recently, a rich source of clinical evidence has demonstrated 63 64 the effectiveness and safety of acupuncture for migraine, showing that acupuncture could effectively reduce the intensity of migraine, frequency of migraine attacks, and number of 65 migraine days (Linde et al., 2016; Vickers et al., 2012). In contrast to the abundant 66 evidence from those clinical trials, the biological basis for the efficacy of acupuncture in 67 relieving migraines remains unclear. 68

To date, several experimental studies have shown that acupuncture alleviates migraine by activating a range of biochemicals in peripheral and pain-related central nuclei (Goldman *et al.*, 2010; Zhao *et al.*,2017) . Goldman et al (2010) found that adenosine and adenosine metabolism mediated the analgesic effect of acupuncture in a mouse model. Zhao et al (2017) showed that calcitonin gene-related peptide (CGRP), which plays a key role in triggering migraine, was suppressed by electroacupuncture in a rat model of migraine. However, there is no validated biomarker associated with the 76 effects of acupuncture for migraine in clinical studies. The explicit biochemical pathways or mechanisms addressing the process of acupuncture relief of migraine are not clear at 77 present. Further, the specific effect of acupuncture relative to sham acupuncture is a long-78 standing controversial topic. Zhao L et al showed in a multicentre randomized trial that 79 acupuncture for migraine is more effective than sham acupuncture (Zhao et al., 2017); 80 others, however, have found no differences (Linde et al., 2005; Li et al., 2012). An 81 individual patient data (IPD) meta-analysis including 20,827 patients confirmed that 82 acupuncture is statistically superior to sham acupuncture for migraine, but the difference 83 84 in effect size between acupuncture and sham was relatively small (Vickers *et al.*, 2012; Vickers et al., 2014). Due to the absence of explainable biological mechanisms for the 85 specific effects of acupuncture, the acceptance of acupuncture as a referable therapy in 86 87 migraine management is still arguable (Linde et al., 2017). Hence, two important questions are raised in this paper: first, are there any biomarkers or pathways that provide 88 a possible mechanism for the efficacy of acupuncture relieving migraine? Second, is 89 there any biological basis attributed to the specific effect of acupuncture compared with 90 sham acupuncture for relieving migraine? 91

Recently, a large number of studies resumed investigation of the pathogenesis of 92 migraine, emphasizing that abnormalities in energy metabolism and mitochondrial 93 function are the fundamental milestones in the pathophysiology of migraine (Colombo et 94 al., 2014; Lodi et al., 2006; Sparaco et al., 2006). Increasing experiments have revealed 95 that insufficient cerebral glycogen unbalances energy metabolism, leading to inhibition of 96 astroglial mitochondrial respiration and excessive production of free radicals. These 97 metabolic changes are attributed to further energy failure in neurons that stimulate 98 cortical expansion depression (CSD) and thus trigger migraine (Finsterer *et al.*, 2018). 99 Moreover, previous studies indicated that the effect of acupuncture may involve multiple 100

101 pathways and dynamic system changes from genomics to metabolomics (Xu et al., 2012). Metabolomics has been powerfully utilized to reveal potential metabolic biomarkers of 102 acupuncture for hypertension (Yang et al., 2018), functional dyspepsia (Wu et al., 2016) 103 and chronic atrophic gastritis (Luo et al., 2013). As such, it is therefore essential to 104 employ metabolomic approaches to pinpoint crucial biomarkers and elucidate the 105 systemic mechanism of acupuncture effects for migraine. Our previous study 106 demonstrated that acupuncture could adjust metabolic profiling in an acute migraine rat 107 model (Gao et al., 2014). Nevertheless, the challenge from statistical methods for dealing 108 109 with high-dimensional metabolomic data still limits the use of metabolomics in acupuncture research. Within this context, machine learning techniques, such as the least 110 absolute shrinkage and selection operator (Lasso), are promising tools for reducing high-111 dimensional data and selecting accurate biomarkers for metabolomics (LeWitt et al., 112 2017; Menni et al., 2017). 113

To investigate the potential metabolic mechanism for the efficacy of acupuncture 114 relief of migraine, we employed ¹H- Nuclear magnetic resonance (NMR) metabolomic 115 technology to detect plasma metabolic phenotypes for 40 female migraine patients who 116 randomly received either acupuncture or sham acupuncture from a total of 476 patients in 117 a randomized controlled trial, together with a group of 10 healthy persons. Using 118 orthogonal signal correction for partial least square discriminate analysis (OPLS-DA), we 119 120 determined different metabolic profiles among healthy controls and migraine patients treated with acupuncture or sham acupuncture. Next, we conducted Lasso regression to 121 select metabolic biomarkers for discriminating acupuncture and sham acupuncture and 122 123 validated the selected metabolites using analysis of variance (ANOVA) combined with Box-Cox transformations and Bonferroni corrections. Further, we validated the 124 performance of Bonferroni-corrected significant metabolic biomarkers discriminating 125

migraine patients at baseline, healthy people and migraine patients after acupuncture in a clinical setting by receiver operating characteristic (ROC) curve analysis. Finally, we complemented our analysis with 2 Bonferroni-corrected significant metabolites and 2 discriminated metabolic pathways attributed to the specific effect of acupuncture using Ingenuity Pathway Analysis (IPA), revealing a novel metabolic mechanism for the efficacy of acupuncture in relieving migraine (Figure 1).

- 132
- 133 **Results**

134 Baseline characteristics and clinical effects of acupuncture

A total of 476 migraine patients were included in the multicenter trial (Li et al., 135 2012), and 40 eligible female patients were enrolled in the 4-week baseline period and 136 137 randomized into the true electroacupuncture (EA) and sham electroacupuncture groups (Sham EA) (22 in the EA group, 18 in the Sham EA group) of the metabolomic study. 138 These 40 patients finished the 4-week baseline assessment and the 4-week EA or Sham 139 EA treatment (Figure 1). There are 39 patients with migraine who meet the definition of 140 migraine without aura, only one migraine patient with aura was recruited in the study. 141 And this patient dropped out in the end of electroacupuncture treatment and not included 142 in the statistical analysis. The baseline characteristics and clinical outcomes were based 143 144 on the intention-to-treat (ITT) population in this study. We omitted the cases that retained only the baseline measurement but had missing data in all clinical outcomes. No 145 significant difference between the two groups was found for any demographic 146 characteristics of all included patients, including age, sex, height, weight, or disease 147 148 status of the patients, such as duration of disease, number of days with migraine, and visual analogue scale (VAS) that assesses pain severity (Table 1, Table S1). 149

After 4 weeks of EA treatment, patients in the EA group showed a significant reduction in days (P = 0.006) and frequency (P = 0.039) of migraines as well as a 152 decrease in VAS scores for pain intensity (P = 0.047) compared to the baseline period (Table 1). In contrast, patients in the Sham EA group also showed a decrease in all three 153 symptoms, but this decrease was not statistically significant (P > 0.05) (Table 1). 154 However, there was no significant difference between the EA group and the Sham EA 155 group in alleviating migraine (Table 1). Our results were consistent with the multicentre 156 trial of acupuncture for migraine by Yin Li (Li et al., 2012). Since a significant difference 157 may not explain the real magnitude of the clinical effect of acupuncture, we further 158 calculated the effect size to validate the efficacy of acupuncture in the context of the 159 160 clinical setting (Zhao et al., 2017).

After 4 weeks of treatment, the effect size measured by Cohen's D in the EA group 161 compared to the baseline period was 0.50 (95% CI, 0.17 to 0.82) for the reduction in the 162 number of migraine days, 0.71 (95% CI, 7.03e-05 to 1.41) for the decrease in the 163 frequency of migraines and 0.61 (95% CI, -0.26 to 1.47) for the decrease in VAS scores 164 (Table 1). In the context of our study, these effect sizes beyond 0.5 in the EA group 165 manifested that the effect sizes in the EA group are, on average, 0.5 standard deviations 166 greater for relieving those symptoms of migraine than those during the baseline period 167 (Ben et al., 2020). However, the effect sizes in the Sham EA group compared to the 168 baseline period were 0.65 (95% CI, -0.042 to 1.34) for the reduction in the number of 169 migraine days, 0.36 (95% CI, -0.44 to 1.17) for the decrease in frequency of migraines 170 171 and 0.14 (95% CI, -0.36 to 0.63) for the decrease in VAS scores (Table 1). These results of effect size were partly in accordance with the large IPD meta-analysis by Vickers et al 172 (Vickers *et al.*, 2012), although they were not statistically significant. Specifically, the 173 174 effect size in the EA group was 0.585 (95% CI, -0.19 to 1.36) compared to the Sham EA group, which means that the EA group is, on average, 0.585 standard deviations greater 175 for decreasing VAS scores than the Sham EA group (Table 1). 176

178 Metabolic discrimination between migraine and healthy controls

We employed ¹H NMR techniques and Chenomx NMR Suite 4.5 (Chenomx, 179 Calgary, Canada) to identify 22 metabolites that were measured in a total of 50 plasma 180 samples from migraine patients in the baseline period (MA, n = 40) and healthy controls 181 (n = 10) (Figure 2 and Table 2). After excluding outliers of abnormal metabolic profiles 182 and baseline values among included migraine patients using PCA analysis, we first 183 performed orthogonal signal correction for partial least square discriminate analysis 184 185 (OPLS-DA) on the normalized Carr-Purcell-Meiboom-Gill (CPMG) NMR data to distinguish metabolic profiles of migraine patients in the baseline period from the profiles 186 of the healthy controls. By using SIMICA-P statistical software, OPLS-DA analysis 187 demonstrated a distinct separation between the MA group and healthy controls (Figure 188 3A x-axis; $R^2Y = 75.8\%$). For the above score plot, R^2Y manifested the proportion of the 189 variance in the y variable explained by the regression model (Wang et al., 2014). Thus, 190 the separation in the plot manifested a crucial metabolic phenotype difference between 191 migraine patients and healthy controls. Correspondingly, the loading plot showed the 192 information of the possible metabolites separating the metabolic profiling (Figure 3B), 193 such as glycine, glutamine, and alanine. After we identified the distinct metabolites in the 194 loading plot, we subsequently conducted Lasso regression, ANOVA combined with Box-195 Cox transformations and Bonferroni correction on the CPMG dataset to further explore 196 potential metabolic biomarkers separating the profiles of migraine patients and healthy 197 198 controls. The dominant metabolites that discriminate these two groups are presented in Table 2. After Bonferroni correction, we found a significant increase in 5 plasma 199 metabolites, including glycerine (P = 0.00085), choline (P = 0.004), citrate (P = 0.016), 200 pyruvic acid (P = 0.049) and glutamine (P = 0.0017), and a significant decrease in 3 201

202 plasma metabolites, including glycine (P = 0.0017), alanine (P = 0.002), and lipid (P =0.030) in the MA group compared to healthy controls. We further conducted ROC curve 203 analysis to validate the clinical importance of these biomarkers. The result of the ROC 204 curve analysis showed that citrate performs well in differentiating between migraine 205 patients and healthy persons (area under the curve (AUC) = 0.87, P = 0.005) (Figure 4C). 206 Moreover, we conducted OPLS-DA analysis on the 1 H NMR longitudinal eddy 207 current delay (LED) dataset, and the LED results also illustrated a similar separation 208 between the MA group and the healthy control group (Supplementary Figure 2C and 209 Supplementary Table 2; $R^2Y = 99.7\%$). Accordingly, we found a significant decrease in 210 plasma N-acetyl glycoproteins (NAc) (P=0.00082) and a significant increase in plasma 211 phosphatidylcholine (Ptdcho) (P = 0.035) in the MA group compared to the healthy 212 control group after Bonferroni correction (Table S2). These significantly changed 213 metabolites found in the CPMG and LED results were selected as potential biomarkers 214 for the metabolic features of migraine in the clinical setting. 215

216

217 Acupuncture reversing metabolic profiling and plasma citrate of migraine

The main objective of our study was to investigate the possible metabolic 218 mechanism for the effectiveness of acupuncture treatment for migraine. Thus, after 219 demonstrating the metabolic profiling of migraine patients, we next explored whether 220 acupuncture changed the metabolites of migraine patients after 20 sessions of EA 221 treatment. Similarly, we performed OPLS-DA analysis on metabolomic data between 222 migraine patients during the baseline period (MA; n = 22) and migraine patients after 223 acupuncture treatment (EA; n = 22). To determine the trend of acupuncture altering 224 225 metabolites, we also conducted an OPLS-DA analysis on the metabolomic data of the 226 two aforementioned groups and 10 healthy controls (n = 10). After 20 sessions of EA at

227 Shaoyang Meridian acupoints over 4 weeks, we observed that the metabolic profiles of the EA group were close to those of the healthy control group but differed from those of 228 the group at baseline (Figure 3C; $R^2Y = 94.5\%$), showing that EA restores the metabolic 229 profiles of migraine similar to those of healthy controls. We further achieved a clear 230 discrimination in metabolic profiling between migraine patients during the baseline 231 period and migraine patients after acupuncture treatment (Figure 3D; $R^2Y = 85.2\%$). 232 Notably, we demonstrated a significant decrease in the plasma levels of citrate (P =233 0.00079) and pyruvic acid (P = 0.012) in the EA group compared to the MA group after 234 Bonferroni correction (Table 3). This result indicated that EA relieves migraine by 235 altering the levels of plasma citrate and pyruvic acid in the clinical setting. In addition, 236 we found a significant increase in plasma lactic acid (P = 0.031) and a significant 237 decrease in plasma acetoacetate (P = 0.025) in the EA group relative to the group at 238 baseline before EA treatment. Further, we found that glycerine (P = 0.00016) was 239 significantly elevated in the EA group compared to the healthy control (Table 3). These 240 significantly changed metabolites were potential metabolite biomarkers for EA relieving 241 migraine. The LED data also showed a clear differentiation between migraine patients 242 during the baseline period and migraine patients after acupuncture treatment (Figure S2C; 243 $R^2Y = 99\%$). A significant decrease in NAC (P = 0.00073) was found in the EA group 244 245 compared with the healthy control group after Bonferroni correction (Table S3). Taken together, these data demonstrated that EA could enhance anaerobic glycolysis by 246 lowering the plasma levels of citrate and pyruvic acid as well as increasing the plasma 247 level of lactic acid. These regulations in energy metabolism and the tricarboxylic acid 248 cycle (TCA) cycle may be the basis of how acupuncture restores metabolic profiles and 249 relieves migraine in a clinical setting. 250

251

252

Metabolic basis for the specific effect of acupuncture

The second objective of our study was to detect the metabolic basis for the specific 253 effect of acupuncture in comparison with sham acupuncture. To address this question, we 254 next performed an OPLS-DA analysis on both CPMG and LED data comparing true 255 acupuncture (EA, n = 22) and sham acupuncture (Sham EA, n = 18) groups. To 256 distinguish the trend of acupuncture adjusting metabolic profiles, OPLS-DA analysis was 257 performed on metabolomic data from healthy controls (n = 10), true acupuncture (EA, n 258 = 22), and sham acupuncture (Sham EA, n = 18) groups. After 20 sessions of Sham EA 259 260 treatment on non-acupoints for 4 weeks, we found that the metabolic profile of the Sham EA group (patients in the Sham EA group after treatment; n = 18) was separated from the 261 healthy controls but similar to the MA group (patients in the Sham EA group before 262 treatment; n = 18) (Figure 3E, $R^2Y = 48.9\%$). Moreover, the OPLS-DA analysis was 263 unable to differentiate MA group and Sham EA group (Figure 3F, $R^2X = 89.9\%$). In 264 addition, the OPLS-DA results also demonstrated an important discrimination in 265 metabolic profiling among EA, Sham EA and healthy controls (Figure 3G; $R^2Y = 88.5\%$), 266 which illustrated that the metabolic profiling of the EA group was close to the healthy 267 controls in relation to the Sham EA group. The difference in the metabolic profiles 268 suggested that EA treatment, not Sham EA treatment, could reverse the metabolic 269 270 profiles of migraine patients to healthy controls. Further, the OPLS-DA results showed a clear separation of the metabolic profiles between the EA group and Sham EA group 271 (Figure 3H, $R^2Y = 94.8\%$), which indicates a discriminated metabolic phenotype between 272 acupuncture and sham acupuncture. The cross-validation for the OPLS-DA analysis of 273 the aforementioned groups was conducted using CV-ANOVA within SIMICA-P 274 software, and the results are provided in Supplementary Table S6. 275

276	Corresponding to the OPLS-DA analysis, after Bonferroni correction, ANOVA
277	results showed a significant decrease in pyruvic acid ($P = 0.047$) in the Sham EA group
278	compared to the MA group (Table 4). Similarly, we found a significant decrease in lipid
279	(P = 0.0012), glycine $(P = 0.000013)$, and alanine $(P = 0.0016)$ as well as a significant
280	increase in glycerine ($P = 0.021$) and glutamine ($P = 0.000013$) in the Sham EA group
281	compared with the healthy control (Table 4). These metabolite changes induced by Sham
282	EA reflect the potential metabolic basis for the effect of sham acupuncture on migraine.
283	Specifically, by using Lasso regression analysis, glycine, glycerine, alanine, 3-
284	hydroxybutyric acid (3-HB), isoleucine (leu_lle), low density lipoprotein_very low
285	density lipoprotein (LDL_VLDL), acetoacetate and glutamine were further selected as
286	potential biomarkers for the discrimination of EA and Sham EA (Table 5). Notably, we
287	found that glutamine ($P = 0.0098$) was significantly decreased in the EA group compared
288	to the Sham EA group (Table 5). Combined, these data demonstrate that there is a distinct
289	metabolic difference between EA and Sham EA. These metabolic differences, which can
290	be caused by plasma changes in glycine, glycerine, alanine, 3-HB, leu_lle, LDL_VLDL,
291	acetoacetate, and glutamine, are a potential metabolic basis for the specific effects of
292	acupuncture.

293

294 **Functional regulation and network adjustment by acupuncture**

After pinpointing the potential metabolic biomarkers for the clinical efficacy of acupuncture, we conducted a metabolic pathway and network analysis among the healthy control, MA, EA and Sham EA groups to further explore the potential upstream pathological mechanisms of acupuncture for migraine. By using IPA, we observed a significant change in the tRNA charging pathway (P = 0.031) and a top-changed metabolic network of carbohydrate metabolism, molecular transport, and small molecule biochemistry (score = 14) (Krämer *et al.*, 2014) between the healthy control and MA
groups (Figure S3A, D).

After 20 sessions of EA treatment for 4 weeks, we found that the pyruvate 303 fermentation to lactate pathway (P = 0.0175) was significantly reversed between the MA 304 and EA groups and that the carbohydrate metabolism, energy production, and lipid 305 metabolism networks (score = 9) were the top changed networks between the MA and 306 EA groups (Figure S3B, E). These results manifested that acupuncture reversed the levels 307 of citrate and pyruvic acid through pyruvate fermentation to the lactate pathway, and 308 309 changed the similar carbohydrate metabolism network, which was altered in migraine patients compared to healthy controls. The changed network of energy production in the 310 EA group further supports the effect of EA based on regulations in energy metabolism 311 from our previous results. Specifically, we found that the tRNA charging pathway (P =312 0.0307) was significantly discriminated between the EA group and Sham EA group 313 (Figure S3C), and the top network discriminating the EA group and Sham EA group was 314 carbohydrate metabolism, molecular transport, and small molecule biochemistry (score 315 =14, Figure 4C). Glycerine was located near the center of the metabolic network of EA 316 compared to Sham EA (Figure 4C). These findings indicate that the metabolic difference 317 found between EA and Sham EA treatment was linked to the tRNA charging pathway 318 and carbohydrate metabolism, molecular transport, and small molecule biochemistry. 319 320 These significantly changed metabolic pathways and networks may be the functional basis of the specific effects of EA compared with sham EA. 321

322

323 **Discussion**

Here, we have described the first metabolomic study of acupuncture for migraine derived from a randomized controlled trial. By using validated NMR techniques and well-designed machine learning strategies, we demonstrated that EA at acupoints could restore energy deficiency and adjust plasma citrate levels, thereby alleviating migraine. Using advanced Lasso regression models, we first determined 8 metabolic biomarkers that can be attributed to the potential metabolic basis for specific effects of acupuncture compared to sham acupuncture. Taken together, these results demonstrated a distinct metabolic phenotype that can serve as a novel scientific explanation for the efficacy of acupuncture in the clinical setting.

The strength of this study includes a concealed central randomization and strict 333 machine learning statistical strategy. Compared with other metabolomics studies for 334 335 acupuncture, the use of central randomization in our study could minimize the selection bias, and the independent of statistician could also lower the detection bias, thus improve 336 the reliability and validity of our study result in clinical setting (Zhao et al., 2017). 337 Specially, Lasso regression was executed, to eliminate the multicollinearity between 338 metabolites and the inter-metabolite relationships comprising the metabolic network 339 (LeWitt et al., 2017, Menni et al., 2017). By using this shrinkage method, 8 potential 340 biomarkers distinguishing the acupuncture and sham acupuncture can be selected. 341 Moreover, Box-cox transformation was applied before the ANOVA analysis, which 342 could be a powerful procedure for adjusting skewed distributions and continuous 343 variables, thereby improving accuracy of statistical results (Yu et al., 2022). Further, 344 Bonferroni correction, one of the strictest multiple testing correction methods, was 345 executed in the study. This method not only could control the false positive rate, but also 346 pinpointed the validated biomarker for acupuncture (Sedgwick et al., 2014). Simply put, 347 we presented a novel and practical machine learning strategy in a randomized 348 349 acupuncture trial, which could set a possible example for handling high-dimensional 350 metabolomics data in acupuncture trials.

351 In this study, we found that EA was more clinically important to patients than sham EA, especially for relieving the intensity of pain in migraine patients. First, EA, not sham 352 EA, could significantly alleviate these clinical symptoms in migraine. Second, the effect 353 size of the VAS score for pain relief in the EA group was markedly higher than that in the 354 Sham EA group (Table 1). The EA group showed an average decrease of 1.05 cm more 355 in the total 10 cm VAS compared with the Sham EA group, and this decrease reached the 356 1 cm MID in the VAS scale (Thorlund K et al., 2011), which accounted for 10.5% 357 greater pain relief than Sham EA treatment at clinic. These results were further in 358 359 agreement with a long-term randomized trial on acupuncture for migraines (Zhao et al.,2017). In addition, the nonsignificant results observed in both acupuncture groups 360 after treatment can be attributed to the limit of statistical significance for small sample 361 sizes as well as the penetration needles in sham EA, which had already been analyzed in 362 a large IPD meta-analysis (Vickers et al., 2012; Li et al., 2012). 363

Recently, accumulating evidence has confirmed that energy deficiency and 364 mitochondrial dysfunction are two cornerstones of migraine pathophysiology (Lodi et 365 al.,2006; Sparaco et al.,2006). A novel metabolic picture of migraine has been presented 366 in a publication of Nature Reviews Neurology (Gross et al., 2019): Decreased cerebral 367 glycogen prolonged synaptic activity, increased cerebral excitability, reduced CSD 368 threshold, and thus stimulated CSD in migraine. On the other hand, mitochondrial 369 370 dysfunction induced excessive production of free radicals and subsequently activated transient receptor potential (TRP) channels that increase CGRP release, which is pivotal 371 for mediating migraine attack. Compared with former studies, we have shown enhanced 372 373 aerobic glycolysis and reduced gluconeogenesis, which trigger the increase in citrate as a key intermediate in the TCA cycle and lead to mitochondrial energy metabolism disorder 374 in migraine patients. Lipid metabolism is also affected and disordered, accompanied by 375

376 an increase in fat mobilization, glycerine and ketone bodies (Table 2, Figure 5) (Aurora et al.,2007; Bélanger et al., 2011). These findings further detailed the imbalance between 377 reduced energy supplies and increased energy needs among migraine patients (Figure 5). 378 In addition, we demonstrated that citrate performed well in discriminating migraine 379 patients and healthy controls, revealing a potential novel biomarker for migraine. It has 380 been shown that an increase in citrate could activate transient receptor potential channel 381 A1 (TRPV1) pain receptors, enhance the protein kinase B (AKT) signaling pathway 382 (Figure S3D) (Gross et al., 2019; Liu et al., 2017; Xu et al., 2018; Chen et al., 2017), 383 384 thereby trigger migraine (Table 2, Figure 5). Collectively, our findings not only expanded the pathophysiology of migraines with an additional understanding of metabolism, but 385 also highlighted the demands of efficient metabolic strategies for migraine treatment. 386

Previously, there is little understanding about the metabolic basis of acupuncture in 387 relieving migraine. Here, we provided novel metabolic evidence of EA relieving 388 migraine as follows: (i) EA could enhance anaerobic glycolysis through converting 389 increased pyruvic acid into lactic acid and subsequently decrease the elevated level of 390 citrate in the TCA cycle and acetoacetate in lipid metabolism in migraine patients (Figure 391 5). (ii) Importantly, citrate, which was found to be significantly increased in migraine 392 patients, was significantly decreased after EA treatment, which provides direct metabolic 393 evidence of EA adjusting mitochondrial function in migraine (Table 2, Figure 5). To date, 394 395 both experimental and clinical evidence has shown that the depletion of glycogen and hypoglycaemia can trigger migraine attacks (Lodi R et al., 2006; Pearce et al., 1971; 396 Hockaday et al., 1971). And lactic acid is a prior energy source for neurons during brain 397 398 energy deficiency (Suzuki et al., 2011). Therefore, the first possible metabolic mechanism for EA relieving migraine is the increased anaerobic glycolysis caused by EA 399 combined with the increase in lactic acid, which can quickly compensate for the lack of 400

401 energy and thereby possibly reduce the CSD triggering migraines (Figure 5). Accordingly, a PET-CT study (Zeng et al., 2012; Yang et al., 2012) also revealed that EA 402 could restore glucose metabolism in key regions of the descending pain modulation 403 system (DPMS) of brain for migraine. Interestingly, our findings identified a potential 404 subgroup of migraine patients with a distinct metabolic phenotype that could benefit from 405 EA treatment in clinics. Moreover, previous results have indicated an important role of 406 mitochondrial dysfunction in migraine and the positive association between citrate levels 407 and activation of the AKT signaling pathway (Gross et al., 2019; Liu et al., 2017; Xu et 408 409 al., 2018; Chen et al., 2017). Recent animal experiment further demonstrated inhibition of the activation of AKT could attenuate cumulative pain score and pain-related 410 behaviors (Xu et al., 2019). Thus, the second potential metabolic evidence of EA 411 managing migraine is that EA could adjust mitochondrial dysfunction and inhibit the 412 pain-related AKT pathway by decreasing the plasma level of citrate, thereby alleviating 413 pain in migraine (Figure 5). In particular, this metabolic biomarker of citrate may serve as 414 the desired quantitative biomarker for further clinical acupuncture research. Third, in the 415 previous decades, profound acupuncture experiments focused on the pivotal role of 416 opioid peptides and its related Arc-PAG-NRM-spinal dorsal horn pathway in mediating 417 acupuncture analgesia (Zhao et al., 2008; Huang et al., 2002). Compared to those 418 neurological evidence of acupuncture analgesia, our results revealed a systemic 419 420 modulation effect of EA on both energy metabolism and mitochondrial function in migraine patients. These findings opened exceptional new insights into the metabolic 421 mechanism underlying the effectiveness of acupuncture analgesia and could be developed 422 423 into potent non-opioid drugs and multi-metabolic therapeutic targets for future migraine 424 treatment.

425 The specific effect of acupuncture is another long-debated issue among clinical acupuncture trials. Fei Y et al and Prof. Gordon Guyatt pointed out in the publications of 426 BMJ that one of the specific methodology challenges in acupuncture trials is the 427 estimation for the optimal treatment effect of acupuncture compare to sham acupuncture 428 (Fei *et al.*, 2022). Here, we presented a unique metabolic mechanism for the specific 429 effect of acupuncture: We demonstrated that there are important but different ways of 430 energy supply between EA and Sham EA for relieving migraine. (i) EA specifically 431 reversed the deficiency of energy metabolism in migraine patients through anaerobic 432 433 glycolysis compared with Sham EA. In detail, EA can restore energy deficiency by enhancing anaerobic glycolysis and decomposition of acetoacetate (Table 2, Figure 5) in 434 the plasma (Salek et al., 2017; Peek et al., 2020), which could quickly compensate for the 435 lack of energy and thereby reduce the CSD triggering migraine. In contrast, sham EA 436 may partially supply energy to migraine patients by fat mobilization through lipid 437 metabolism (Table 3). In addition, the network analysis showed that glycerine, a classic 438 product of fat mobilization, was the key node in the metabolic network of EA compared 439 with sham EA (Figure 4C). Therefore, we can postulate the hypothesis that these 440 different ways of supplying energy may be one of the crucial factors contributing to the 441 different effect between acupuncture and sham acupuncture. (ii) EA specifically relieves 442 migraine by reversing citrate, thereby adjusting mitochondrial dysfunction compared with 443 sham EA. The TCA cycle is the centre of energy metabolism in the body. In particular, 444 we have shown that EA, not sham EA, could reverse plasma citrate and subsequently 445 adjust the dysfunction of the TCA cycle in mitochondria, thus restoring metabolic 446 profiling and relieving migraine in migraine patients (Figure 5). (iii) We found that 447 448 glutamine, a classic excitatory neurotransmitter that facilitates CSD and is linked to the intensity of migraine (Gao et al., 2014; Aroke et al., 2020; Alam et al., 1998), showed a 449

450 Bonferroni-corrected significant decrease in the EA group compared with the Sham EA group. This result is consistent with our previous metabolomic study of an acute migraine 451 rat model (Gao et al., 2014). The significant decrease in glutamine in the EA group 452 relative to the Sham EA group further explains why EA had a better clinical migraine 453 pain relief effect than sham EA. In addition, our study found that both EA and sham EA 454 could significantly increase glycerine levels, thereby supplying energy to migraine 455 patients. This finding gives a possible explanation for the non-specific effect of EA and 456 sham EA observed in these clinical trials. Collectively, the specific effect of EA on both 457 anaerobic glycolysis and mitochondrial function for migraine exclusively provides a 458 possible scientific mechanism of the efficacy of acupuncture for clinical doctors and 459 clinical decision-makings. 460

In summary, our findings indicate that EA specifically relieves migraine by 461 enhancing anaerobic glycolysis and decreasing the plasma levels of citrate and glutamine 462 among migraine patients. Our study is of great importance because it provides scientific 463 evidence and explanations for the specific effect of acupuncture relieving migraine for 464 both clinical doctors and policymakers. By applying modern machine learning 465 techniques, this metabolic evidence could enlighten a brand new direction into 466 acupuncture analgesia mechanism, which in turn would pose fresh challenges for future 467 acupuncture researches. 468

469

470 Limitations of the study

The main limitation of this study is the limited sample size and the non-targeted metabolic technique which cannot detect targeted metabolite changes in the TCA cycle and glucose metabolism. And the validated animal experiment should also be executed. 474 Future studies will extend this work using a larger sample size of migraine patients and

475 targeted metabolomics on both human and animals for possible validation experiments.

476

477 Materials and methods

478 Ethics approval

The clinical trial protocol was approved by the Ethics Review Committee of the 1st Teaching Hospital of Chengdu University of TCM and had been published [2007KL-002] (Li *et al.*, 2008). The multicentre randomized trial was registered (clinicaltrials.gov: NCT00599586). All study procedures were designed and conducted in accordance with principles of the Declaration of Helsinki and the Chinese version of the International Conference on Harmonisation --- Good Clinical Practice. All patients signed written informed consent.

486

487 **Participants**

From April 1, 2008, to August 12, 2009, 476 migraine patients were recruited in the 488 multicentre trial. And the migraine patients included in this metabolomic study were all 489 recruited from a single trial centre, the 1st Teaching Hospital of Chengdu University of 490 TCM, which is one of the clinical centers in the multicentre trial. To be included, the 491 492 migraine patients had to meet the International Headache Classification criteria for migraines (ICHD-II 2004) (Headache Classification Subcommittee of the International 493 Headache Society, 2004), as diagnosed by a doctor. The inclusion criteria were as 494 495 follows: age from 20 to 45 years old; female only; Han nationality; onset of migraines before age 45; more than 1 year of migraine history and acute migraine attacks 2 to 8 496 times per month during the previous three months; no use of any prophylactic drug for 497 migraine during the previous 2 weeks; body mass index (BMI) ranging from 18-24; no 498 heart, liver, or kidney disease detected by ultrasound or blood tests as well as other 499

serious organic diseases; willingness to complete 20 acupuncture treatments for 4 weeks;and ability to provide written informed consent.

We excluded patients who had headache owing to organic disorders (e.g., cerebrovascular disease, vascular malformation, arthritic conditions, arteriosclerosis or hypertension) or patients with psychosis, pregnancy or lactation, allergies, bleeding disorders or serious diseases of the heart, liver, kidney or other organs.

Healthy females without migraine who had no significant differences in age, gender,
or BMI compared to migraine patients were recruited as the healthy control group.

508

509 **Randomization and interventions**

The overall trial approach is shown in Figure 1. Forty female patients who met the 510 inclusion criteria were randomly assigned to the electroacupuncture group at specific 511 acupoints belonging to the Shaoyang Meridian group (EA) or the electroacupuncture 512 group at non-acupoints (Sham EA) using a central randomization procedure controlled by 513 the Chengdu Good Clinical Practice (GCP) Center. Central randomization was conducted 514 by a GCP center computer. The independent study assistant sent the patient's information 515 516 to the GCP centre through email or short message service (SMS) message. Random numbers and group assignments were accordingly generated by a GCP computer and sent 517 back to the study assistant by a feedback email or SMS. Acupuncturists were not 518 519 involved in patient recruitment in this trial. Patients and outcome assessors were blinded to randomization. Patients were informed that they would receive one of two types of 520 acupuncture treatment: one was based on traditional Chinese acupuncture theories and 521 522 another was using modern acupuncture theory.

Acupuncture treatment was performed unilaterally, alternately at specific acupoints of Waiguan (TE5), Yanglingquan (GB34), Qiuxu (GB40), and Fengchi (GB20), which 525 belong to Shaoyang Meridian of the hand and foot in the EA group (Figure 2A). Degi sensation was required for the EA group. In contrast, sham acupuncture treatment was 526 conducted unilaterally, alternately at predefined non-acupoints, including the middle 527 point between the tip of the elbow and the axilla, the middle point between the 528 epicondylus medialis of the humerus and the ulnar side of the wrist on the ulnar side, the 529 edge of the tibia 1 to 2 cm lateral to the Zusanli (ST36), and the anterior border of the 530 insertion of the deltoid muscle at the junction of the deltoid and biceps muscles in the 531 medial arm (Li et al., 2008) (Figure 2A). Degi sensation was not required for the Sham 532 533 EA group. All acupoints and sham acupoints were punctured by disposable stainless steel needles $(0.25 \square mm \square \times \square 40 \square mm; 0.25 \square mm \times \square 25 \square mm;$ Suzhou Hwato Medical 534 Appliance Co., Ltd., 2270202, Suzhou City, China) at a depth of 20 mm-40 mm. In 535 addition to normal puncturing, 4 auxiliary needles were punctured 2 mm beside every 536 acupoint or non-acupoint with a depth of 2 mm without manual stimulation (Li et 537 al.,2008). Transcutaneous electroacupuncture stimulation was subsequently conducted at 538 the acupoints or sham acupoints for 30 minutes using a Han's acupoint nerve stimulator 539 (HANS-200, Nanjing, China) after needle insertion. The stimulation frequency was set at 540 2/15 Hz, and the intensity varied from 0.1 mA to 1 mA, adjusted in accordance with the 541 patient's perception. All acupuncture procedures were conducted in accordance with 542 standards for reporting interventions in clinical trials of acupuncture (STRICA) 543 (MacPherson *et al.*, 2010) and a predefined acupuncture SOP by a licensed acupuncturist 544 with at least 5 years of clinical acupuncture experience and with a completed 545 postgraduate degree. Acupuncture treatment was performed 5 times per week according 546 547 to the patient's convenience, and a total of 20 acupuncture treatments were performed on both the EA and Sham EA groups. The patients were instructed not to take regular 548 medications during acupuncture treatment. However, ibuprofen (300 mg each capsule 549

with sustained release) could be used as rescue medication when severe migraine attacks

551 happened.

552

553 **Outcomes and sample collection**

The number of days with migraine before and after four weeks of treatment was 554 defined as the primary outcome for evaluating the frequency of migraine attack. This 555 outcome was recorded in a migraine diary by the migraine patients during the baseline 556 and four-week treatment period. Together with the number of days with migraine, the 557 558 frequency of migraine and the visual analog scale (VAS) were also recorded by the migraine patients in the same period. The visual analog scale (VAS) is a validated and 559 reliable instrument for assessing pain severity and alleviation. On this scale, pain is 560 measured by placing a handwritten mark on a 10-centimeter line representing a 561 continuum between "no pain" (0 cm) and "worst pain" (10 cm) (10cm). This provides a 562 pain severity rating in centimeters out of ten, such as six out of ten (or 6/10) (Delgado et 563 al., 2018). Measurements of the frequency and pain intensity of migraine were secondary 564 outcomes. A total of two blood samples were collected for metabolomics analysis at the 565 start of acupuncture treatment and at the end of 4 weeks of treatment. All fasting venous 566 blood samples (approximately 5 mL) were collected at approximately 7:30–9:30 am and 567 then stored at -80°C. 568

569

570 NMR experiments

⁵⁷¹ ¹H NMR spectra of the plasma samples were collected and analysed as described in ⁵⁷² our previous study (Gao *et al.*, 2014). 1 sample from acupuncture group (migraine ⁵⁷³ patients after acupuncture treatment) and 1 sample from sham acupuncture group ⁵⁷⁴ (migraine patients after sham acupuncture treatment) were not qualified to be analyzed ⁵⁷⁵ before experiment. Prior to NMR analysis, plasma samples were thawed and centrifuged ⁵⁷⁶ at 13000 × g, 4 °C for 10min. 300 μ L of each supernatant was transferred into 5mm NMR ⁵⁷⁷ tube, mixed with 250 μ L of D₂O for field frequency lock and 50 μ L of 3-trimethylsilyl-⁵⁷⁸ ²H₄-propionic acid sodium salt (TSP) in D₂O (1mg/mL) as chemical shift reference. All ⁵⁷⁹ samples contained a final volume of 600 μ L and were vortexed repeatedly.

¹H NMR data of plasma were acquired on a Varian INOVA 600 MHz NMR 580 spectrometer at 27 °C using a Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse 581 sequence, with a total spin-spin relaxation delay $(2n\tau)$ of 320 ms. Water suppression was 582 achieved by selective saturation of the water peak during the recycle delay (2s) and 583 mixing time TM of 150 ms. Free induction decays (FIDs) were collected into 32,000 data 584 585 points with a spectral width of 8,000Hz over 64 scans. The FIDs were then zero-filled by a factor of two and multiplied by an exponential line-broadening factor of 0.5Hz prior to 586 Fourier transformation. The diffusion-edited experiments were also carried out with 587 bipolar pulse pair-longitudinal eddy current delay (BPP-LED) pulse sequence. The 588 gradient amplitude was set at 35.0 G/cm with a diffusion delay of 100 ms. A total of 128 589 transients and 16,000 data points were collected with a spectral width of 8,000 Hz. A 590 line-broadening factor of 1 Hz was applied to FIDs before Fourier transformation (Wang 591 *et al.*, 2004). 592

All NMR spectra were manually phased and baseline-corrected using VNMR 6.1C software (Varian Inc.). For CPMG spectra, each spectrum over the range of δ 0.4–4.4 was integrated into segments of equal width (0.01 ppm). The spectrum between δ 5.2-8.5 was discarded due to the week signal of aromatic amino acids and the potential lack of association with migraine according to previous studies (Dejong *et al.*,2007; Harder *et al.*,2021). For BPP-LED data, each spectrum over the range of δ 0.1–6.0 was segmented into integral regions of equal width (0.01ppm). The regions containing the residual

signals of water (δ 4.6–5.1) were excluded. Interval correlation shifting (icoshift) 600 technique in MATLAB package (version 7.0) were employed to conduct peak alignment. 601 It uses a Fast Fourier Transform (FFT) engine and a greedy algorithm that allows align 602 all spectra simultaneously (Savorani *et al.*,2010). To accommodate these large intensity 603 or concentration variations, the integral values of each spectrum were normalized to a 604 constant sum of all integrals in a spectrum in order to minimize the impacts of 605 concentration variation between samples after ppm segmentation. This total spectrum 606 area (TSA) normalization method performed well in representing NMR spectral 607 intensities (Emwas et al., 2018). Identification of metabolites in the spectra was achieved 608 based on literatures and the Chenomx NMR Suite 4.5 (Chenomx, Calgary, Canada) and 609 the HMDB database (http://www.hmdb.ca/). Specific compounds with multiple peaks 610 were determined by combining the relevant ppm corresponding to the most obvious 611 peaks in the normalized data. Figure 2B identifies and displays the major plasma 612 metabolites. The CPMG pulse sequence was used to emphasize the resonances of small 613 metabolites in plasma, while resonances from macromolecules were attenuated (Figure 614 2B). Supplementary Figure 1 shows diffusion-edited NMR spectra of plasma from each 615 group, displaying the signals of lipid, N-acetylglycoproteins (NAc) groups of 616 glycoproteins. Subtle differences in these spectra were observed by visual examination 617 among groups. Following the identification of metabolites, relative concentration of 618 metabolites could be estimated by the defined area of peak among different group. 619 Further analysis was conducted using supervised learning statistical techniques to 620 621 discriminate potential metabolic differences among the four groups.

- 622
- 623 Statistical analysis
- 624 Clinical statistics

625 The overall statistical strategy used in this study is shown in Figure 1. The clinical variables were analyzed using R software (version 3.54). The baseline characteristics and 626 clinical outcomes were based on the intention-to-treat (ITT) population. We omitted the 627 cases that retained only the baseline measurement but had missing data in all clinical 628 outcomes. If the data were normally distributed, we planned to use ANOVA to detect the 629 differences in numerical variables and performed χ^2 tests for categorical variables. If data 630 were not normally distributed, we planned to apply the Kruskal-Wallis test. Continuous 631 data were described as the mean (SD) with 95% CIs. Categorical data were illustrated as 632 633 numbers and percentages. A one-sided test was executed for available data under hypothesis testing in superiority. A P-value <0.05 was defined as statistically significant. 634 Clinical effect sizes were calculated by the R package "effectsize" using the cohen.d 635 method (Ben et al., 2020). The standardized effect size is defined as the difference in 636 means between two groups divided by the pooled standard deviation. The minimal 637 important difference (MID) for the VAS was calculated and defined by the empirical 638 work from Thorlund et al (2011), and it stands for the smallest difference in pain relief 639 that patients regarded as important on average. 640

641

642 **Pattern recognition**

The resulting integral data were transformed into SIMCA-P (version 14.0; Umetrics,
Ume°a, Sweden) for pattern recognition analysis. Before analysis, CPMG data and BPPLED data were Pareto-scaled, in terms of variance stabilization (Worley B, *et al.*,2013).
For the purpose of discriminating differences in metabolic profiling among the groups,
CPMG data and LED data were both subjected to principal component analysis (PCA).
To detect and exclude the outlier of abnormal metabolic profile among included migraine
patients, PCA was first performed on the normalized ¹H NMR dataset after Pareto scaling

650 in this study (Mickiewicz B, et al., 2013). A principal component (PC) score plot and loading plot were used to visualize the data. On the score plot, each point represents an 651 individual sample, and on the loadings plot, each point indicates a single NMR spectral 652 region. In the score plot, R^2Y displayed the proportion of the sum of squares for the 653 selected component, which accounts for the proportion of the variance in the responsible 654 (y) variable explained by the regression model (Figure S2A,B) (Wang et al., 2004). 655 Furthermore, OPLS-DA was performed to maximize separation and remove variance that 656 was not related to group membership. CV-ANOVA method was also carried out for the 657 658 cross-validation of OPLS-DA analysis within SIMCA-P software. Metabolites with an impact on differentiation were ranked on the basis of the variables of importance 659 parameter (VIP) method coupled with OPLS-DA, which assesses each variable's relative 660 influence on the model. The metabolites with a value of VIP > 1 were selected and listed 661 as potential biomarkers for the discrimination of model (Menni et al., 2017). 662

663

664 **Biomarker discovery and validation**

To discover potential metabolite biomarkers for the effects of acupuncture, we 665 developed a strict statistical machine learning strategy that is used for this study (see 666 supplementary Fig. S4). Initially, the Shapiro-Wilks test was performed on raw data to 667 check the normal distribution. Following that, OPLS-DA analysis and VIP method are 668 conducted to achieve discrimination between groups and select potential biomarkers. 669 After obtaining the list of potential metabolic biomarkers for migraine and acupuncture 670 from VIP method, a Lasso regression was performed on the normalized metabolomic 671 data using the glmnet package in R to identify the most significant metabolites 672 determinants of change for migraine and acupuncture. The overall penalty parameter α 673 was set to 1 to select those with the highest predicted value of metabolites in glmnet. 674

675 Tenfold internal cross-validation with cy.glmnet function was applied to validate the regression model and to achieve the minimum lambda(λ), the best predict parameter for 676 Lasso regression in the model. Through using this minimum λ yielded the most optimized 677 model, the most relevant metabolites distinguishing migraine, acupuncture and sham 678 acupuncture could be subsequently selected (Friedman et al., 2010). For the validation of 679 potential metabolic biomarkers, ANOVA with Box-Cox transformed method was 680 subsequently performed on these metabolites to obtain the Bonferroni-corrected P-value 681 with the Mass package in R (Venables et al., 2002; Blaise et al., 2016). Following the 682 683 analysis from VIP method, LASSO regression and ANOVA, a Venn diagram was generated to determine the overlapping metabolites selected by three aforementioned 684 statistical methods (Supplementary Fig. S4). The overlap of statistically significant 685 metabolites (P < 0.05 after Bonferroni correction) common to all three statistical 686 methods were identified as validated biomarkers of migraine and acupuncture. Finally, 687 receiver operating characteristic (ROC) curve analysis was performed to evaluate the 688 diagnostic abilities of these validated biomarkers for migraine and acupuncture. 689 GraphPad Prism version 7.0 (GraphPad Software, United States) was used to perform this 690 ROC analysis. For the calculated area under the curve (AUC) of the biomarker, an AUC 691 of 0.9–1.0 suggested excellent performance, and 0.8–0.89 indicated good performance, 692 while AUC < 0.6 showed nonsignificant diagnostic performance (Haase-Fielitz et 693 694 al.,2009). Employing this consistent statistical strategy, we were able to subsequently select and narrow the potential biomarkers from series of metabolites and pinpointed the 695 most validated biomarkers for migraine and acupuncture (Yu Y et al., 2020). 696

697

698 **Pathway and network analysis**

699 Ingenuity Pathway Analysis (IPA) software (IPA build version: 364062M, content 2015-12-12, version: 26127183. release date: analysis date: 2018-11-30, 700 http://www.ingenuity.com/) (QIAGEN, Redwood City, CA, USA) was used to explore 701 potential targeted pathways and networks related to both migraine and the effect of 702 acupuncture in an unbiased way. The ratios of metabolites between two groups, including 703 healthy controls vs. migraine group, acupuncture group vs. migraine group, acupuncture 704 group vs. sham acupuncture group, were calculated and inputted into IPA software for 705 pathway analysis of migraine and the efficacy of acupuncture. IPA's Core Analysis 706 707 module was subsequently used for pathway analysis. Fisher's exact test was used to produce a P-value determining the probability that the link between the metabolites and 708 the canonical pathway was explained only by chance. Canonical pathways with a *P*-value 709 710 < 0.05 after Bonferroni correction were regarded as statistically significant pathways contributing to the pathology of migraine and the potential effect of acupuncture. Based 711 on the 'master' network, which was developed from the Ingenuity Knowledge Base, a 712 causal network was established to reflect observed cause-effect relationships among 713 chemicals, protein families, complexes and biological processes. The network score was 714 calculated using the hypergeometric distribution, with Fisher's exact test at the right tail 715 yielding the negative logarithm of the significant threshold. Z-score > 2 was defined as 716 the threshold of significant activation for network analysis, disease, and function, while 717 718 Z-score < 2 was defined as the threshold of significant inhibition. The score of the networks also reflects the probability of molecules gathering in this network. When the 719 number of metabolites gathering in this network increases, the score will also increase 720 721 (Krämer et al., 2014; Kriebel et al., 2016). Following the IPA analysis, the summary of 722 significant pathways and important networks were presented in the supplementary Fig. S3. 723

724

725 **Data and availability**

All data, models, or code used during the study are available from the corresponding author by request.

728

729 Acknowledgements

We grateful acknowledge Prof. Xuguang Liu, Prof. Qiaofeng Wu, Prof. Zongxiang Tang, Prof. Xiaopei Shen, Prof. Fangrong Yan for their help and guide during the experiment. We thank the staff from Top Grade TCM Science Technology Laboratory of State Administration of TCM of China for the collection of blood samples of the subjects.

735

736 **Funding**

This work was supported by grants from the National Basic Research Program of China
(973 Program, nos. 2012CB518501 and 2006CB504501), National Natural Science
Foundation of China (no. 81973941, no. 81202741), State Scholarship Fund (no.
201608320044).

741

742 Author Contributions

Jointly supervised research, F.L, S.Y, X.Y, C.G.; Conceived and designed the

experiments, F.L, S.Y, X.Y.; Performed the experiments, Z.G, Q.C, L.J, X.Y; Performed

statistical analysis, Z.G, C.M, C.G.; Contributed reagents, materials, or analysis tools,

R.W.S, S.S, S.M, B.K, R.W, J.A, S.B.; Contributed to data exploration, Z.G, G.Y, F.G,

L.J,U.M,C.G.; Wrote the paper, Z.G., X.Y, C.G. All authors discussed the results and

reviewed the final manuscript.

749

750 Figure Titles and Legends

751 **Fig. 1 Study design**

We conducted a non-targeted metabolomic study of 40 migraine patients and 10 healthy

- people. Plasma was collected before and after EA or Sham EA treatment for ${}^{1}H$ NMR
- 754 experiments.
- 755

Fig. 2: Locations of acupuncture points and typical ¹H NMR spectra of plasma samples.

(A) Locations of acupuncture points at Shaoyang meridian and non-acupoints

- 759 **(B)** Typical ¹H NMR CPMG spectra of plasma samples.
- ¹H NMR experiments were carried out, and Chenomx NMR Suite 4.5 (Chenomx,
- Calgary, Canada) software was used to identify 22 metabolites measured in a total of 50 plasma samples from 40 migraine patients and 10 healthy controls before and after EA or sham EA treatment (Table 2). a1, migraine patients; ZC, healthy controls; Ala, alanine; Cr/Crn, creatine; Gly, glycine; gln, glutamine; glu, glutamate; Val, valine; 3-HB, 3- hydroxybutyric acid; Leu/lle, isoleucine; Different citrate levels of migraine patients indicate that there is a difference at the citrate level in the spectra.
- 767

768 Fig. 3 Clear separation of metabolic profiles among groups.

- OPLS-DA analysis for CPMG data manifested clear separation among migraine patients (red dots), healthy controls (black boxes), migraine patients after 4 weeks of EA treatment (blue diamonds), and migraine patients after 4 weeks of sham EA treatment (purple stars). t[1] and t[2] represent the first and second components in the OPLS-DA result, respectively.
- The missing samples from the EA group and Sham EA group on the score plots were excluded due to the outlier and drop out.
- (A) Clear separation of metabolic profiling was achieved between migraine (red dots,
- n=40 and healthy control (black boxes, n=10) groups.
- (B) Corresponding loading plots showing metabolites that may influence the separation
- for (a). Gly, glycine; Gln, glutamine; Lac, lactic acid; Ala, alanine.

- (C) The separation of metabolic profiling showed that EA treatment (blue diamonds, n=22) reversed the change in metabolic profiling in migraine patients (red dots, n=22)
- compared with healthy controls (black boxes, n=10) (*Table 3*).
- (**D**) The results showed a clear discrimination in metabolic profiling between migraine patient after EA treatment (blue diamonds, n=22) and migraine patients before EA treatment (red dots, n=22) (*Table 3*).
- 786 (E) The results showed that migraine patient after sham EA treatment (purple stars, n=18)
- could not restore the change of metabolic profiling in migraine patient before sham EA
- treatment (red dots, n=18) compared with healthy controls (black boxes, n=10) (*Table 4*).
- 789 (F) The result showed metabolic profiling of migraine patient before Sham EA treatment
- 790 (red dots, n=18) could not be discriminated with migraine patient after Sham EA
- 791 treatment (purple stars, n=10) (*Table 4*)
- (G) The profiling indicated that the metabolic profiling of migraine patients after EA
 treatment (blue diamonds) was closer to that of healthy controls (black boxes) compared
 to migraine patients after sham EA treatment (purple stars).
- (H) Clear separation of metabolic profiling was discriminated between EA treatment(blue diamonds) and sham EA treatment (purple stars) (*Table 5*).
- 797

798 Fig. 4 Identification of significant metabolites for the clinical efficacy of acupuncture

- We conducted receiver operating characteristic (ROC) curve analysis to validate the significance of potential biomarkers for migraine and acupuncture.
- (A) ROC analysis showed that citrate could significantly discriminate the migraine and
 control groups and thus might be a potential diagnostic biomarker (AUC=0.87) for
 migraine diagnosis.
- (**B**) Citrate was significantly decreased (P = 0.00079) after EA treatment.
- 805 (C) Employing IPA network analysis, we found that glycerine (glycerol), glycine, 806 acetone, alanine and leucine might be important metabolites for the metabolic network of 807 EA vs sham EA. Glycerine (glycerol), which is located near the centre of the metabolic 808 network of EA vs sham EA, may be the key metabolite for the efficacy of EA and sham 809 EA (C) (*Table 5*).
- 810

Fig. 5 The metabolic mechanism for the efficacy of acupuncture in migraine

The black arrow (\uparrow/\downarrow) shows the depletion of glucose metabolism and increased lipid metabolism in migraine patients, leading to energy deficiency and disorder of the TCA

814	cycle and mitochondria, which trigger migraine attack. The red arrow (\uparrow/\downarrow) and the blue
815	box indicate the possible metabolic mechanism of acupuncture, which suggests that EA
816	may restore energy deficiency by enhancing anaerobic glycolysis and lowering plasma
817	citrate levels in the TCA cycle, thus decreasing migraine attack and restoring
818	mitochondrial function and metabolic profiling in migraine patients.
819	
820	Tables
821 822 823	Table 1. Clinical outcome measurements between the EA and Sham EA groupsbefore and after treatment
824 825 826	Table 2. Changes in plasma metabolites in CPMG NMR spectra between healthycontrols and migraine patients
827 828 829	Table 3. Changes in plasma metabolites in CPMG NMR spectra before and afterEA treatment in migraine patients
830 831 832	Table 4. Changes in plasma metabolites in CPMG NMR spectra before and aftersham acupuncture treatment in migraine patients
833 834 835	Table 5. Changes in plasma metabolites in CPMG NMR spectra between EA andsham EA treatment
836	Supplementary information
837	Supplementary Fig. S1 Typical 1H NMR LED spectra of plasma samples.
838	Supplementary Fig. S2 Clear separation of metabolic profiles among groups.
839	Supplementary Fig. S3 Identification of significant pathway among three groups.
840	Supplementary Fig. S4 Statistical strategy for integrating different set of metabolic
841	biomarkers from diverse statistical methods in the study.
842	Supplementary Table S1. Baseline characteristics.
843	Supplementary Table S2. Changes in plasma metabolites in LED NMR spectra between
844	healthy controls and migraine patients
845	Supplementary Table S3. Changes in plasma metabolites in LED NMR spectra before
845 846	Supplementary Table S3. Changes in plasma metabolites in LED NMR spectra before and after EA treatment in migraine patients.
845 846 847	Supplementary Table S3. Changes in plasma metabolites in LED NMR spectra before and after EA treatment in migraine patients. Supplementary Table S4. Changes in plasma metabolites in LED NMR spectra before

- 849 Supplementary Table S5. Changes in plasma metabolites in LED NMR spectra between
- EA and sham EA treatment
- Supplementary Table S6. cv-anova results of OPLS-DA analysis corresponding for scoreplots
- 853

854 **Reference**

- Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB. Plasma levels of
 neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol
 Sci 1998; 156:102-106.
- Aroke EN, Powell-Roach KL. The Metabolomics of Chronic Pain Conditions: A
 Systematic Review. Biol Res Nurs 2020; 15:1-14.
- Aurora SK, Wilkinson F. The brain is hyperexcitable in migraine. Cephalalgia 2007;
 27:1442–53.
- Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyteneuron metabolic cooperation. Cell Metab 2011; 14:724–738.
- Ben-SM, Makowski D, Lüdecke D. "Compute and interpret indices of effect size."
 CRAN 2020;R package, https://github.com/easystats/effectsize
- 866 Blaise BJ, Correia G, Tin A, Young JH, Vergnaud AC, Lewis M, Pearce JT, Elliott P,
- Nicholson JK, Holmes E, Ebbels TM. Power Analysis and Sample Size Determin
 ation in Metabolic Phenotyping. Anal Chem 2016; 17:5179-88.
- 869 Chen SP, Zhou YQ, Liu DQ, Zhang W, Manyande A, Guan XH, Tian YK, Ye DW,
- 870 Omar DM. PI3K/Akt Pathway: A Potential Therapeutic Ta- rget for Chronic Pain.
- 871 Curr Pharm Des 2017; 23:1860-1868.
- Colombo B, Saraceno L, Comi G. Riboflavin and migraine: the bridge over troubl ed
 mitochondria, Neurol Sci 2014; 35: Suppl 1,141-144.
- ⁸⁷⁴ Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris
- JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-

- 877 2018;2(3):e088.
- ⁸⁷⁸ Dejong CH, van de Poll MC, Soeters PB, Jalan R, Olde Damink SW. Aromatic amino
- acid metabolism during liver failure. J Nutr. 2007;137(6 Suppl 1):1579S-1585S

based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev.

- 880 Emwas AH, Saccenti E, Gao X, McKay RT, Dos Santos VAPM, Roy R, Wishart DS.
- 881 Recommended strategies for spectral processing and post-processing of 1D 1H-NMR
- data of biofluids with a particular focus on urine. Metabolomics. 2018;14(3):31.
- Fei YT, Cao HJ, Xia RY, Chai QY, Liang CH, Feng YT, Du YR, Yu MK, Guyatt G,
- Thabane L, Lao LX, Liu JP, Zhang YQ. Methodological challenges in design and conduct of randomised controlled trials in acupuncture. BMJ. 2022;376:e064345.
- Finsterer J, Zarrouk-Mahjoub S. Headache in mitochondrial disorders. Clin Neurol
 Neurosurg. 2018;166:44-49.
- Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models
 via C- oordinate Descent. J Stat Softw 2010; 33:1-22.
- Gao Z, Liu X, Yu S, Zhang Q, Chen Q, Wu Q, Liu J, Sun B, Fang L, Lin J, Zhu BM, Yan
- 891 X, Liang F. Electroacupuncture at Acupoints Reverses Plasma Glutamate, Lipid, and
- LDL/VLDL in an Acute Migraine Rat Model: A (1) H NMR-Based Metabolomic
- Study. Evid Based Complement Alternat Med 2014; 2014:1-14.
- Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, Jensen TK, Pei Y, Wang F, Han X,
 Chen JF, Schnermann J, Takano T, Bekar L, Tieu K, Nedergaard M. Adenosine A1
 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci.
 2010;13(7):883-8.
- Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine
 from pathophysiology to treatment. Nat Rev Neurol 2019;15:627-643.
- 900 Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, Haase
- M.Novel and conventional serum biomarkers predicting acute kidney injury in adult
 cardiac surgery-a prospective cohort study. Crit. Care Med 2009; 37:553-560.
- Harder AVE, Vijfhuizen LS, Henneman P, Willems van Dijk K, van Duijn CM, Terwindt
 GM, van den Maagdenberg AMJM. Metabolic profile changes in serum of migraine
 patients detected using 1H-NMR spectroscopy. J Headache Pain. 2021 Nov
 24;22(1):142.
- Headache Classification Subcommittee of the International Headache Society. The
 international classification of headache disorders: 2nd edition. Cephalalgia 2004;
 24:9-160.

- 910 Hockaday JM, Williamson DH, Whitty CW. Blood-glucose levels and fatty-acid
- 911 metabolism in migraine related to fasting. Lancet 1971; 297:1153–1156.
- Huang C, Wang Y, Han JS, Wan Y. Characteristics of electroacupuncture-induced
- analgesia in mice: variation with strain, frequency, intensity and opioid involvement.
- 914 Brain Res. 2002;945:20-25.
- Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity
 Pathway Analysis. Bioinformatics 2014; 15: 523-30.
- 917 Kriebel J, Herder C, Rathmann W, Wahl S, Kunze S, Molnos S, Volkova N, Schramm K,
- 918 Carstensen-Kirberg M, Waldenberger M, Gieger C, Peters A, Illig T, Prokisch H,
- 819 Roden M, Grallert H. Association between DNA Methylation in Whole Blood and
- 920 Measures of Glucose Metabolism: KORA F4 Study. PLoS One. 2016 Mar
- 921 28;11(3):e0152314. doi: 10.1371/journal.pone.0152314.
- 922 LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP
- Investigators. Metabolomic Biomarkers as Strong Correlates of Parkinson Disease
 Progression. Neurology 2017; 88:862-869.
- Linde K, Streng A, Jürgens S, Hoppe A, Brinkhaus B, Witt C, Wagenpfeil S, Pfaffenrath
- V, Hammes MG, Weidenhammer W, Willich SN, Melchart D.Acupuncture for
- patients with migraine: a randomized controlled trial. JAMA 2005; 293: 2118-2125.
- Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, Vickers A, White AR.
 Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev
 2016; 6:CD001218.
- Linde K. Evidence of effectiveness but not efficacy why many complementary therapies
 are so hard to accept for biomedicine. BMC Complementary and Alternative
 Medicine 2017; 17:S3.
- ⁹³⁴ Li Y, Liang F, Yu S, Liu X, Tang Y, Yang X, Tian X, Yan J, Sun G, Chang X, Zheng H,
- Zhang H, Ma T.Randomized controlled trial to treat migraine with acupuncture:design and protocol. Trials 2008;20:57.
- ⁹³⁷ Li Y, Zheng H, Witt CM, Roll S, Yu SG, Yan J, Sun GJ, Zhao L, Huang WJ, Chang XR,
- 238 Zhang HX, Wang DJ, Lan L, Zou R, Liang FR. Acupuncture for migraine prophylaxis:
- a randomized controlled trial. CMAJ 2012; 184: 401-410.

- Liu YY, Jiao ZY, Li W, Tian Q. PI3K/AKT signaling pathway activation in a rat model
 of migraine. Mol Med Rep 2017; 16:4849-4854.
- Lodi R, Tonon C, Testa C, Manners D, Barbiroli B. Energy metabolism in migraine.
 Neurol Sci 2006; 27 Suppl 2: S82-85.
- Luo HG, Chen JX, Zhang Q, Yue GX, Ding J, Zhang HT, Yan XZ, Zhao X, Meng ZZ.

645 Comparative study on effects of Xiaoyao Powder and its modified prescription on

plasma metabolomics of rats with chronic immobilization Stress. Chinese Journal of
Integrative Medicine 2013; 19:610-615.

MacPherson H, Altman DG, Hammerschlag R, Li Y, Wu T, White A, Moher D;

949 STRICTA Revision Group. Revised standards for reporting interventions in clinical

- trials of acupuncture (stricta): extending the consort statement. PLoS Med 2010; 7: 1-
- 951 11.
- 952 Menni C, Migaud M, Kastenmüller G, Pallister T, Zierer J, Peters A, Mohney RP,
- Spector TD, Bagnardi V, Gieger C, Moore SC, Valdes AM. Metabolomic Profiling of
 Long-Term Weight Change: Role of oxidative Stress and Urate Levels in Weight
 Gain. Obesity 2017; 25:618-1624.
- Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach
 for early diagnosis of pediatric septic shock and its mortality. Am J Respir Crit Care
 Med. 2013;187(9):967-76.
- Pearce J. Insulin induced hypoglycaemia in migraine. J. Neurol. Neurosurg. Psychiatry
 1971; 34:154–156.
- Peek AL, Rebbeck T, Puts NA, Watson J, Aguila MR, Leaver AM. Brain GABA and
 glutamate levels across pain conditions: A systematic literature review and metaanalysis of 1H-MRS studies using the MRS-Q quality assessment tool. Neuroimage
 2020; 210:116532.
- Salek T, Andel I, Kurfurstova I. Topiramate induced metabolic acidosis and kidney
 stones a case study. Biochem Med (Zagreb) 2017; 27:404-410.
- Savorani F, Tomasi G, Engelsen SB. icoshift: A versatile tool for the rapid alignment of
 1D NMR spectra. J Magn Reson. 2010;202(2):190-202.
- Sedgwick P. Multiple hypothesis testing and Bonferroni's correction. BMJ. 2014;20:

970 349:g6284.

- Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction
 and migraine: evidence and hypotheses. Cephalalgia 2006; 26:361-372.
- 973 Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, Alberini CM.
 974 Astrocyte-neuron lactate transport is required for long-term memory formation. Cell.
 975 2011;144(5):810-23.
- Thorlund K, Walter SD, Johnston BC, Furukawa TA, Guyatt GH. Pooling Health-Related
 Quality of Life Outcomes in Meta-Analysis-A Tutorial and Review of Methods for
 Enhancing Interpretability. Res Synth Methods 2011; 3:188-203.
- Venables, W. N. & Ripley, B. D. Modern Applied Statistics with S. Fourth Edition.
 Springer 2002; New York. ISBN 0-387-95457-0.
- Vickers AJ, Cronin AM, Maschino AC, Lewith G, MacPherson H, Foster NE, Sherman
- 982 KJ, Witt CM, Linde K; Acupuncture Trialists' Collaboration.Acupun cture for chronic
- pain: individual patient data meta-analysis. Arch Intern Med 2012;172:1444-1453.
- Vickers AJ, Linde K. Acupuncture for chronic pain. JAMA 2014; 311: 955-956.
- Wang Y, Holmes E, Nicholson JK, Cloarec O, Chollet J, Tanner M, Singer BH, Utzinger
 J. Metabonomic investigations in mice infected with Schistosoma mansoni: an
 approach for biomarker identification. Proc Natl Acad Sci U S A. 2004; 101(34):
- 988 12676-81.
- Wells RE, Bertisch SM, Buettner C, Phillips RS, McCarthy EP. Complementary and
 alternative medicine use among adults with migraines/severe headaches. Headache
 2011;51:1087-1097.

Worley B, Powers R. Multivariate Analysis in Metabolomics. Curr Metabolomics.
2013;1(1):92-107

Wu Q, Zou M, Yang M, Zhou S, Yan X, Sun B, Wang Y, Chang S, Tang Y, Liang F, Yu
S.Revealing Potential Biomarkers of Functional Dyspepsia by Combining 1H NMR
Metabonomics Techniques and an Integrative Multi-objective Optimization Method.
Sci Rep 2016; 6:18852.

Xu B, Mo C, Lv C, Liu S, Li J, Chen J, Wei Y, An H, Ma L, Guan X. Post-surgical
inhibition of phosphatidylinositol 3-kinase attenuates the plantar incision-induced
postoperative pain behavior via spinal Akt activation in male mice. BMC Neurosci.
2019; 20(36):1-10

- Xu W, Zhang L, Huang Y, Yang Q, Xiao H, Zhang D. Discrimination of type 2 diabetes
 mellitus corresponding to different traditional Chinese medicine syndromes based on
 plasma fatty acid profiles and chemometric methods. Journal of Ethnopharmacology
 2012; 143:463-468.
- Xu X, Chen Q, Qiu Z, Shi C, Ding H, Wang L, Lv H, Yu L. Association of cough
 hypersensitivity with tracheal TRPV1 activation and neurogenic inflammation in a
 novel guinea pig model of citric acid-induced chronic cough. J Int Med Res 2018;
 46:2913-2924.
- Yang J, Zeng F, Feng Y, Fang L, Qin W, Liu X, Song W, Xie H, Chen J, Liang F. A
 PET-CT study on the specificity of acupoints thr ough acupuncture treatment in
 migraine patients. BMC Complement Altern Med 2012; 15:1-7.
- Yang M, Yu Z, Chen X, Guo Z, Deng S, Chen L, Wu Q, Liang F.Active Acupoints
 Differ from Inactive Acupoints in Modulating Key Plasmatic Metabolites of
- 1015 Hypertension: A Targeted Metabolomics Study. Sci Rep 2018; 8:17824.
- Yu H, Sang P, Huan T. Adaptive Box-Cox Transformation: A Highly Flexible FeatureSpecific Data Transformation to Improve Metabolomic Data Normality for Better
 Statistical Analysis. Anal Chem. 2022;94(23):8267-8276.
- 1019 Yu Y, Gao Z, Lou J, Mao Z, Li K, Chu C, Hu L, Li Z, Deng C, Fan H, Chen P, Huang H,
- 1020 Yu Y, Ding J, Li D, Chen F. Identification of Serum-Based Metabolic Feature and
- 1021 Characteristic Metabolites in Paraquat Intoxicated Mouse Models. Front Physiol.1022 2020;11:65.
- 1023 Zeng F, Qin W, Ma T, Sun J, Tang Y, Yuan K, Li Y, Liu J, Liu X, Song W, Lan L, Liu
- M, Yu S, Gao X, Tian J, Liang F. Influence of acupuncture treat ment on cerebral
 activity in functional dyspepsia patients and its relationship with efficacy. Am J
 Gastroenterol 2012; 107:1236-1247.
- 1027 Zhao LP, Liu L, Pei P, Qu ZY, Zhu YP, Wang LP. Electroacupuncture at Fengchi (GB20)
 1028 inhibits calcitonin gene- related peptide expression in the trigeminovascular system of
 1029 a rat model of migraine. Neural Regen Res 2017; 12:804-811.
- 1030 Zhao L, Chen J, Li Y, Sun X, Chang X, Zheng H, Gong B, Huang Y, Yang M, Wu X, Li
- 1031 X, Liang F. The long-term effect of acupuncture for migraine prophylaxis: a
- randomized clinical trial. JAMA Intern Med 2017;177:508-515.

- 1033 Zhao, ZQ. Neural mechanism underlying acupuncture analgesia. Prog. Neurobiol 2008;
- 1034 85: 355–375.

1035

Figure. 1 Study design

We conducted a non-targeted metabolomic study of 40 migraine patients and 10 healthy people. Plasma was collected before and after EA or Sham EA treatment for ¹H NMR experiments.





(A) Locations of acupuncture points at Shaoyang meridian and non-acupoints

(B) Typical ¹H NMR CPMG spectra of plasma samples.

¹H NMR experiments were carried out, and Chenomx NMR Suite 4.5 (Chenomx, Calgary, Canada) software was used to identify 22 metabolites measured in a total of 50 plasma samples from 40 migraine patients and 10 healthy controls before and after EA or sham EA treatment (Table 2). a1, migraine patients; ZC, healthy controls; Ala, alanine; Cr/Crn, creatine; Gly, glycine; gln, glutamine; glu, glutamate; Val, valine; 3-HB, 3-hydroxybutyric acid; Leu/lle, isoleucine; Different citrate levels of migraine patients indicate that there is a difference at the citrate level in the spectra.



Figure. 3 Clear separation of metabolic profiles among groups.

OPLS-DA analysis for CPMG data manifested clear separation among migraine patients (red dots), healthy controls (black boxes), migraine patients after 4 weeks of EA treatment (blue diamonds), and migraine patients after 4 weeks of sham EA treatment (purple stars). t[1] and t[2] represent the first and second components in the OPLS-DA result, respectively. The missing samples from the EA group and Sham EA group on the score plots were excluded due to the outlier and drop out.

(A) Clear separation of metabolic profiling was achieved between migraine (red dots, n=40) and healthy control (black boxes, n=10) groups.

(**B**) Corresponding loading plots showing metabolites that may influence the separation for (a). Gly, glycine; Gln, glutamine; Lac, lactic acid; Ala, alanine.

(C) The separation of metabolic profiling showed that migraine patient after EA treatment (blue diamonds, n=22) reversed the change in metabolic profiling in migraine patients before EA treatment (red dots, n=22) compared with healthy controls (black boxes, n=10) (Table 3).

(**D**) The results showed a clear discrimination in metabolic profiling between migraine patient after EA treatment (blue diamonds, n=22) and migraine patients before EA treatment (red dots, n=22) (Table 3).

(E) The results showed that migraine patient after sham EA treatment (purple stars, n=18) could not restore the change of metabolic profiling in migraine patient before sham EA treatment (red dots, n=18) compared with healthy controls (black boxes, n=10) (Table 4).

(**F**) The result showed metabolic profiling of migraine patient before Sham EA treatment (red dots, n=18) could not be discriminated with migraine patient after Sham EA treatment (purple stars, n=18) (Table 4)

(G) The profiling indicated that the metabolic profiling of migraine patients after EA treatment (blue diamonds) was closer to that of healthy controls (black boxes) compared to migraine patients after sham EA treatment (purple stars).

(H) Clear separation of metabolic profiling was discriminated between EA treatment (blue diamonds) and sham EA treatment (purple stars) (Table 5).





Figure. 4 Identification of significant metabolites for the clinical efficacy of acupuncture

We conducted receiver operating characteristic (ROC) curve analysis to validate the significance of potential biomarkers for migraine and acupuncture.

(A) ROC analysis showed that citrate could significantly discriminate the migraine and control groups and thus might be a potential diagnostic biomarker (AUC=0.87) for migraine diagnosis.

(B) Citrate was significantly decreased (P = 0.00079) after EA treatment.

(C) Employing IPA network analysis, we found that glycerine (glycerol), glycine, acetone, alanine and leucine might be important metabolites for the metabolic network of EA vs sham EA. Glycerine (glycerol), which is located near the centre of the metabolic network of EA vs sham EA, may be the key metabolite for the efficacy of EA and sham EA (C) (Table 5).



Figure. 5 The metabolic mechanism for the efficacy of acupuncture in migraine

The black arrow (\uparrow/\downarrow) shows the depletion of glucose metabolism and increased lipid metabolism in migraine patients, leading to energy deficiency and disorder of the TCA cycle and mitochondria, which trigger migraine attack. The red arrow (\uparrow/\downarrow) and the blue box indicate the possible metabolic mechanism of acupuncture, which suggests that EA may restore energy deficiency by enhancing

anaerobic glycolysis and lowering plasma citrate levels in the TCA cycle, thus decreasing migraine attack and restoring mitochondrial function and metabolic profiling in migraine patients.



Outcome	EA group	Sham EA group	T value	P value	Effect size
	$(n = 22^{\#})$	$(n = 18^{\#})$	(EA vs Sham)	(EA vs Sham)	(EA vs Sham)
Number of days with					
migraine					
Baseline,	7.53(5.42)	6.46(3.46)	0.61	0.54	
mean,(sd),(95 % CI)	(4.25 to 10.81)	(4.54 to 8.38)			
End of treatment, mean,	4.92(5.13)	4.57(2.73)	0.21	0.82	0.086(-0.71 to
(sd),(95 % CI)	(1.81 to 8.02)	(2.99 to 6.15)			0.88)
	2(1/2.97)	2.07(2.64)	0.42	0.66	0.16
Difference in means	2.61(2.87)	2.07(3.64)	0.43	0.66	0.16
End of treatment-	(0.87 to 4.35)	(-0.034 to 4.17)			
baseline, mean, (sd),					
(95 % CI)	3 28	2 12			
P value	0.0065**	0.053			
Effect size	0.5003	0.65(-0.042to			
	0.30 (0.17 to 0.02)	0.03(0.01210			
		1.35)			
Frequency of					
migraines					
Baseline,	4.69(2.05)	4.26(2.28)	0.51	0.60	
mean, (sd), (95 % CI)	(3.44 to 5.93)	(3.00 to 5.53)			

End of treatment, mean,	3.15(2.26)	3.57(1.45)	-0.56	0.57	0.22(-0.57 to
(sd), (95 % CI)	(1.78 to 4.52)	(2.73 to 4.41)			1.02)
End of	1.53(2.40)	0.71(2.78)	0.82	0.41	0.32
treatment-baseline,	(0.086 to 2.98)	(-0.89 to 2.32)			
mean, (sd), (95 % CI)					
t value	2.30	0.95			
P value	0.039*	0.35			
Effect size	0.71(7.03e-05 to 1.42	0.36(-0.44 to 1.17)			
)				
VAS score					
Baseline,	4.11(1.32)	4.49(1.60)	-0.70	0.48	
mean, (sd), (95 % CI)	(3.31 to 4.91)	(3.63 to 5.35)			
End of treatment,	3.24(1.53)	4.29(1.95)	-1.60	0.12	0.585(-0.19 to
mean,(sd), (95 % CI)	(2.31 to 4.17)	(3.24 to 5.33)			126)
					1.30)
End of	0.86(1.99)	0.25(1.74)	0.85	0.40	0.33
treatment-baseline,	(-0.33 to 2.07)	(-0.71 to 1.22)			
mean, (sd), (95 % CI)					
t value	1.81	0.568			
P value	0.047*	0.573			
Effect size	0.61 (-0.26 to 1.47)	0.14 (-0.36 to 0.64)			

*P < 0.05; **P < 0.01. # The baseline characteristics and clinical outcomes were based on the intention-to-treat (ITT) population. We omitted the cases that retained only the baseline measurement but had missing data for all clinical outcomes.

Metabolism	Metabolites	Peak Regions	Con (n=10)	Mig (n=40)	Direction of	adjP
		-	mean(sd)	mean(sd)	effect	Mig vs Con
					Mig vs Con	
	Glucose	3.89	173.93(12.32)	171.37(12.02)	\downarrow	0.56
	Lactic acid	1.32	276.77(52.99)	266.91(55.56)	Ļ	0.62
Glucose	Nac	2.03-2.04	168.04(12.44)	161.05(13.89)	\downarrow	0.16
metabolism	3-HB	1.19-1.20	35.50(31.16)	41.81(23.59)	↑	0.53
	Acetoacetate	2.22	16.24(14.15)	19.64(12.12)	↑	0.49
	Citrate	2.68-2.70	3.25(2.53)	5.73(2.79)	$\uparrow\uparrow$	0.016*
	Pyruvic acid	2.38	2.25 (1.63)	3.47(1.63)	$\uparrow\uparrow$	0.049*
	Acetate	1.91	9.16(3.82)	11.33(5.18)	↑	0.23
	Lipid	1.3	54.38(9.31)	42.78(15.32)	$\downarrow\downarrow$	0.030*
Lipid	Glycerine	3.64-3.66	70.28(11.46)	86.66(12.84)	$\uparrow \uparrow$	0.00085**
metabolism	Ptdcho	3.24	282.6(16.49)	289.60(12.72)	↑	0.16
	Choline	3.22-3.23	256.83(21.51)	284.53(26.08)	$\uparrow \uparrow$	0.00403**
	LDL_VLDL	0.86-0.88	158.52(21.80)	164.31(36.37)	↑	0.63
	Glycine	3.54	239.82(14.61)	212.26(24.63)	$\downarrow\downarrow$	0.0017**
	Alanine	1.46	83.34(18.50)	61.05(18.75)	$\downarrow\downarrow$	0.0020**
Amino acid	Glutamate	2.35-2.36	24.74(5.92)	25.05(7.41)	↑	0.90

Table 2 Changes in plasma metabolites in CPMG NMR spectra between healthy controls and migraine patients

metabolism	Valine	1.03-1.04	104.63(12.72)	103.51(16.66)	\downarrow	0.85
	Leu_lle	0.97-0.99	145.68(16.16)	143.82(21.32)	\downarrow	0.81
	Glutamine	2.43-2.44	94.35(14.19)	88.95(15.23)	\downarrow	0.32
	Cre/Crn	3.03-3.04	35.23(6.39)	38.81(7.72)	↑	0.19
	Isoleucine	0.94	33.51(3.71)	31.71(4.03)	\downarrow	0.21
	Glutamine	2.11-2.12	68.37(11.86)	81.73(17.70)	$\uparrow \uparrow$	0.0017**

The up or down arrow (\uparrow/\downarrow) indicates whether the metabolite showed a signal increase or decrease, respectively. **P*<0.05; ***P*<0.01. Abbreviations: Con, healthy control; Mig, migraine patients from the EA and Sham EA groups before treatment; adjp, p value after Bonferroni correction.

Metabolism	Metabolites	Con (n=10)	Mig (n=22)	Direction	adjP		EA	Direction	adjP	Direction	adjP
		mean(sd)	mean(sd)	of effect	Mig	VS	mean(sd)	of effect	EA vs	of effect	EA vs
				Con vs	Con			EA vs	Con	EA vs	Mig
				Mig				Con		Mig	
	Glucose	173.93(12.32)	166.53(12.35)	Ļ	0.33		171.13(13.78)	Ļ	0.85	↑	0.58
	Lactic acid	276.76(53.0)	269.56(55.83)	\downarrow	0.95		327.16(71.12)	↑	0.12	$\uparrow\uparrow$	0.031*
Glucose	Nac	168.04(12.43)	157.42(14.98)	Ļ	0.18		160.29(15.56)	\downarrow	0.40	1	0.85
metabolism	3-HB	35.50(31.16)	49.46(29.14)	1	0.34		30.36(14.42)	↓	0.89	↓	0.097
	Acetoacetate	16.24(14.15)	21.11(15.45)	↑	0.58		9.26 (6.23)	Ļ	0.35	$\downarrow\downarrow$	0.025*

Table 3 Changes in plasma metabolites in CPMG NMR spectra before and after EA treatment in migraine patients

	Citrate	3.25(2.53)	7.24(2.37)	$\uparrow \uparrow$	0.00019**	4.02 (1.80)	↑	0.65	$\downarrow\downarrow$	0.00079**
	Pyruvic_acid	2.25 (1.63)	4.10 (1.93)	$\uparrow \uparrow$	0.022*	2.32 (1.36)	-	0.995	$\downarrow\downarrow$	0.012*
	Acetate	9.17(3.82)	11.34(5.60)	1	0.45	10.17 (3.40)	↑	0.84		0.76
	Lipid	54.38 (9.31)	46.61(17.20)	Ļ	0.37	40.64(14.21)	\downarrow	0.065	\downarrow	0.49
Lipid	Glycerine	70.28(11.46)	89.79(12.67)	$\uparrow\uparrow$	0.00056**	92.26(11.55)	$\uparrow\uparrow$	0.00016**	↑	0.83
metabolism	Ptdcho	282.60(16.50)	288.13(11.53)	↑	0.63	283.87(17.76)	↓	0.98	Ļ	0.71
	Choline	256.83(21.51)	289.91(27.11)	$\uparrow \uparrow$	0.0053**	283.68 (24.5)	$\uparrow \uparrow$	0.031*	\downarrow	0.76
	LDL_VLDL	158.52(21.80)	162.88(36.51)	1	0.95	156.25(39.11)	↓	0.98	↓	0.85
	Glycine	239.82(14.61)	218.25(28.46)	\downarrow	0.13	217.75(31.54)	\downarrow	0.13	/	0.99
	Alanine	83.34(18.5)	64.71(22.65	\downarrow	0.075	67.57(20.08)	\downarrow	0.17	1	0.91
Amino acid	Glutamate	24.75(5.92)	25.32(8.54)	1	0.98	26.42(8.87)	↑	0.87	↑	0.92
metabolism	Valine	104.63(12.72)	99.78(17.20)	\downarrow	0.675	99.17(12.03)	\downarrow	0.63	/	0.99
	Leu_lle	145.68(16.16)	138.51(22.07)	\downarrow	0.59	139.1(15.84)	\downarrow	0.67	/	0.99
	Glutamine	94.35(14.18)	92.04(18.14)	\downarrow	0.92	83.90(13.86)	\downarrow	0.25	\downarrow	0.33
	Cre_Crn	35.23(6.39)	42.09(8.33)	↑	0.083	36.30(7.95)	1	0.94	\downarrow	0.10
	Isoleucine	33.51(3.71)	31.14(4.86)	\downarrow	0.33	32.14(3.41)	\downarrow	0.70	1	0.77
	Glutamine	68.37(11.86)	79.16(21.54)	$\uparrow\uparrow$	0.045*	73.89(13.72)	1	0.24	\downarrow	0.65

The up or down arrow (\uparrow/\downarrow) indicates whether the metabolite showed a signal increase or decrease, respectively. **P*<0.05; ***P*<0.01. Mig, migraine patients in

EA group before treatment; EA, migraine patients in the EA group after 4 weeks of EA treatment. Con, healthy control. adjp, p value after Bonferroni correction.

Metabolism	Metabolites	Con mean(sd)	Mig mean(sd)	Directio n of	adjP Mig vs	Sham EA mean(sd)	Direction of effect	adjP Sham EA vs	Directi on of	adjP Sham
		(n = 10)	(n = 18)	effect	Con		Sham EA	Con	effect	EA vs
				Con vs			vs Con		Sham	Mig
				Mig					EA vs	
									Mig	
	Glucose	173.94(12.32)	176.51(9.54)	1	0.79	173.66(8.28)	-	0.99	\downarrow	0.79
	Lactic acid	276.77(52.99)	264.10(56.97)	\downarrow	0.85	285.55(89.8)	↑	0.99	↑	0.80
Glucose	Nac	168.04(12.43)	164.91(11.88)	\downarrow	0.79	159.32(9.15)	\downarrow	0.25	\downarrow	0.49
metabolism	3-HB	35.50(31.16)	33.68(12.07)	\downarrow	0.88	27.48(14.54)	\downarrow	0.82	\downarrow	0.50
	Acetoacetat	16.24(14.15)	18.08(7.32)	1	0.54	16.72(12.50)	-	0.97	\downarrow	0.71
	e									
	Citrate	3.25(2.53)	4.14(2.31)	\uparrow	0.50	4.26(2.16)	↑	0.57	/	0.99
	Pyruvic acid	2.25(1.63)	2.81(0.86)	\uparrow	0.29	1.83(1.22)	\downarrow	0.64	$\downarrow\downarrow$	0.047**
	Acetate	9.16(3.82)	11.32(4.88)	↑	0.36	11.28(2.89)	↑	0.35	/	0.97
	Lipid	54.38(9.31)	38.71(12.27)	$\downarrow\downarrow$	0.011*	32.80(12.12)	$\downarrow\downarrow$	0.0012**	\downarrow	0.39
Lipid	Glycerine	70.28(11.46)	83.33(12.54)	$\uparrow\uparrow$	0.019**	84.82(9.98)	$\uparrow\uparrow$	0.021*	↑	0.93
metabolism	Ptdcho	282.60(16.49)	291.15(14.08)	↑	0.30	286.37(12.2)	↑	0.82	\downarrow	0.71
	Choline	256.83(21.51)	278.81(24.46)	\uparrow	0.12	285.47(38.5)	↑	0.08	↑	0.88
	LDL_VLDL	158.52(21.81)	165.83(37.35)	\uparrow	0.92	171.78(36.2)	↑	0.73	↑	0.89
	Glycine	239.82(14.61)	205.91(18.61)	$\downarrow\downarrow$	9.98498	196.28(17.62	Ļ	1.349E-05**	Ļ	0.34
					E-05**)				
	Alanine	83.34(18.5)	57.164(13.1)	$\downarrow\downarrow$	0.0014*	55.11(17.37)	$\downarrow\downarrow$	0.0016**	\downarrow	0.87

Table 4 Changes in plasma metabolites in CPMG NMR spectra before and after sham acupuncture treatment in migraine patients

					*					
Amino acid	Glutamate	24.75(5.92)	24.76(6.27)	-	0.99	24.044(4.51)	-	0.98	-	0.98
metabolism	Valine	104.63(12.72)	107.46(15.62)	1	0.91	108.07(15.7)	1	0.89	-	0.99
	Leu_lle	145.69(16.16)	149.46(19.59)	1	0.89	152.31(20.7)	↑	0.75	\uparrow	0.93
	Glutamine	94.35(14.19)	85.67(11.02)	\downarrow	0.29	85.18(15.72)	\downarrow	0.29	-	0.98
	Cre_Crn	35.24(6.39)	35.33(5.315)	-	0.99	38.33(7.32)	↑	0.56	\uparrow	0.54
	Isoleucine	33.51(3.71)	32.33(2.95)	\downarrow	0.69	31.64(3.86)	\downarrow	0.44	\downarrow	0.85
	Glutamine	68.37(11.86)	84.47(12.57)	$\uparrow\uparrow$	5.302E-	88.57(14.04)	$\uparrow\uparrow$	1.36E-05	↑	0.46
					05**			**		

The up or down arrow (\uparrow/\downarrow) indicates whether the metabolite showed a signal increase or decrease, respectively. **P*<0.05; ***P*<0.01. Mig, migraine patients in sham EA group before treatment; Sham EA, migraine patients in the sham EA group after 4 weeks of sham EA treatment. Con, healthy control. adjp, p value after Bonferroni correction.

Metabolism	Metabolites	EA	Sham EA	Direction of	adjP	Coefficient
		mean(sd)	mean(sd)	effect	EA vs Sham	EA vs Sham
				EA vs Sham	EA	EA
				EA		
	Glucose	171.13(13.78)	173.67(8.28)	↑	0.64	n.a.
	Lactic acid	327.17(71.12)	285.55(89.88)	↑	0.23	n.a.
Glucose	Nac	160.29(15.56)	159.32(9.15)	\downarrow	0.85	n.a.
metabolism	3-HB	30.36(14.42)	27.48(14.54)	\downarrow	0.64	-0.74
	Acetoacetate	9.26(6.23)	16.72(12.50)	↑	0.061	1.06
	Citrate	4.02(1.81)	4.26(2.16)	-	0.72	n.a.
	Pyruvic acid	2.32(1.36)	1.83(1.22)	\downarrow	0.35	n.a.
	Acetate	10.17(3.40)	11.29(2.90)	↑	0.43	n.a.

Table 5 Changes in plasma metabolites in CPMG NMR spectra between EA and sham EA treatment

	Lipid	40.64(14.22)	32.80(12.13)	\downarrow	0.18	n.a.
Lipid	Glycerine	92.26(11.56)	84.824(9.98)	\downarrow	0.12	-0.38
metabolism	Ptdcho	283.87(17.76)	286.38(12.21)	1	0.72	n.a.
	Choline	283.68(24.50)	285.47(38.52)	1	0.87	n.a.
	LDL_VLDL	156.25(39.12)	171.78(36.19)	1	0.35	0.24
	Glycine	217.75(31.53)	196.29(17.62)	\downarrow	0.076	-0.179
	Alanine	67.57(20.08)	55.12(17.37)	\downarrow	0.14	-0.32
Amino acid	Glutamate	26.42(8.87)	24.04(4.51)	\downarrow	0.43	n.a.
metabolism	Valine	99.17(12.03)	108.07(15.70)	1	0.13	n.a.
	Leu_lle	139.10(15.84)	152.31(20.75)	1	0.088	0.19
	Glutamine	83.90(13.86)	85.18(15.72)	1	0.83	n.a.
	Cre_Crn	36.30(7.95)	38.34(7.32)	1	0.55	n.a.
	Isoleucine	32.14(3.41)	31.64(3.86)	\downarrow	0.75	n.a.
	Glutamine	73.89(13.72)	88.56(14.04)	$\uparrow \uparrow$	0.0098**	0.23

The up or down arrow (\uparrow/\downarrow) indicates whether the metabolite showed a signal increase or decrease, respectively. **P*<0.05; ***P*<0.01.

The coefficient was calculated by Lasso regression. EA, migraine patients in the EA group after 4 weeks of EA treatment; Sham EA, migraine patients in the Sham EA group after 4 weeks of Sham EA treatment.